Format

Send to

Choose Destination
Ann Rheum Dis. 2016 Apr;75(4):785-6. doi: 10.1136/annrheumdis-2015-208490. Epub 2015 Dec 23.

Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry.

Author information

1
Department of Rheumatology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark.
2
The Danish Multiple Sclerosis Registry, Neuroscience Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark Department of Neurology, The Danish Multiple Sclerosis Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
3
National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark.
4
Department of Neurology, The Danish Multiple Sclerosis Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
5
Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark.

KEYWORDS:

Ankylosing Spondylitis; Anti-TNF; Rheumatoid Arthritis

PMID:
26698850
DOI:
10.1136/annrheumdis-2015-208490
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center